0.80
+7.64%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About iBio
From its filings with the US Securities and Exchange Commission
iBio is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IBIO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $100,000 and a net loss of $33.0m. At that date it held total assets of $99.1m and shareholders' equity of $85.7m.
We believe the future treatment for obesity lies not just in overall weight loss, but in the quality, durability, and tolerability of weight loss. Current interventional therapies, such as glucagon-like peptide-1 (“GLP-1”) receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability. We are developing next-generation therapies designed with the goal of meeting these unmet needs, by leveraging AI-guided antibody design, advanced screening technologies and deep expertise in biologics development.
Our strategy is built on multiple key principles. First, we aim to develop next-generation antibody therapeutics addressing limitations of currently approved treatments, offering options with the potential to preserve muscle mass, target fat selectively, and provide durable weight loss with improved tolerability. Second, we are prioritizing targets with strong human genetic and clinical validation, which we believe both reduces translational risk and increases the likelihood of clinical success. Third, we are evaluating opportunities in adjacent obesity-related indications, including cardiometabolic and cardiopulmonary conditions such as pulmonary hypertension due to heart failure with preserved ejection fraction (“PH-HFpEF”). Lastly, we are applying our integrated AI Drug Discovery Platform and deep scientific expertise to rapidly generate and advance development-ready biologics, enabling us to move with speed and precision in a competitive and fast-evolving field.
Quoted from its 10-K, filed 28 Aug 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Aug 2008
- Employees
- 20
- Website
- ibioinc.com ↗
- Head office
- 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. William ClarkIndependent Chairman of the Board$134,272
- Dr. Martin BrennerChief Executive Officer, Chief Scientific Officer, Director, since 2021$1.5m
- Mr. Felipe DuranChief Financial Officer$770,081
- Mr. Marc BanjakChief Legal Counsel$712,903
- Mr. David ArkowitzIndependent Director$64,231
- Dr. Alexandra KropotovaIndependent Director$100,346
- Mr. Antonio ParadaIndependent Director$58,154
- Mr. Evert SchimmelpenninkIndependent Director$94,268
- Mr. Gary SenderIndependent Director$117,556
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 57
- Social
- 72
- Governance
- 35
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- iBio's iBioLaunch technology enables plant-based production of biologics in hydroponic systems.
- iBioModulator technology supports development of therapeutic proteins and vaccines.
- iBio focuses on commercializing plant-based protein expression for fibrotic diseases and vaccines.
Weaknesses
- iBio has only 20 employees, limiting operational capacity.
- iBio's IPO was in 2008, indicating limited recent market activity.
- iBio employs only 7 full-time staff, reducing development speed.
Opportunities
- iBio's plant-based biologics platform can expand into enzyme replacement therapies.
- iBio can leverage its technology for monoclonal antibodies development.
- iBio's platform is applicable to recombinant versions of plasma-derived products.
Threats
- iBio faces competition from traditional biotech firms in vaccine development.
- iBio's small employee count may hinder rapid response to market changes.
- iBio's technology is not yet widely adopted in the biotechnology sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.